Trial Summary
Orforglipron is unique because it is an oral, non-peptide drug that targets the GLP-1 receptor, which is different from many other obesity treatments that are injectable. This makes it more convenient for patients who prefer taking a pill over injections.
12345Orforglipron has been studied for safety in people with type 2 diabetes and obesity. In these studies, it was generally well-tolerated, meaning most people did not experience serious side effects.
12345Research shows that Orforglipron, a drug taken by mouth, helped people with obesity lose weight over 26 weeks. This drug works by activating a specific receptor in the body that can help reduce weight.
12345The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Eligibility Criteria
Adolescents with obesity, or overweight with related health issues like hypertension or type 2 diabetes, who've tried losing weight through diet and exercise without success. They must have a BMI in the top percentiles for their age and sex. Those who've lost significant weight recently, plan to undergo bariatric surgery, or have conditions causing secondary obesity can't participate.Inclusion Criteria
Exclusion Criteria